mediKOL Insight: Where next for MS?
mediKOL Ltd.
December 1, 2008 122 Pages - SKU: MDK2194033
|
|
The MS landscape is poised to change dramatically over the next 4 - 7 years as a number of hotly anticipated new therapies enter the latter stages of development with fascinating implications for all stakeholders.
This report provides an in-depth and insightful appraisal of the current and future MS market. It is driven principally by the views of a panel of internationally recognised key opinion leaders (KOLs), whose opinions on the current and future clinical environment are distilled, analysed and presented in clear and insightful commercial terms. More specifically, the report is focused on three potential future scenarios that illustrate how the MS market might evolve based on commercial, clinical and regulatory events, and underpinned by our KOL discussions. The report also presents an overview and appraisal of the key clinical trials together with an analysis of their potential impact on the future market. Individual product and market forecasts are compared and contrasted with ‘consensus’ forecasts supplied under licence from EvaluatePharma®.
|
- Contents
- Table of Contents
- Introduction
- Report Overview
- KOL’s
- Executive Summary
- Executive Summary
- Conclusions
- Commercial Outlook
- Comparative Product Attributes
- Market Development Scenarios 1, 2, 3
- Future Market Scenarios 1, 2 & 3
- The mediKOL View
- Disease Synopsis
- MS Overview
- Epidemiology
- Diagnosis
- Treatment
- Current Market
- The mediKOL View
- Current Landscape
- The Market
- Overview
- Product Summary
- Historic Market Development
- US Pricing
- Drug Treatments
- Beta-interferon
- Avonex
- Betaferon
- Rebif
- Other Products
- Copaxone
- Tysabri
- The mediKOL View
- Future Landscape
- R&D Overview
- Key R&D Issues
- Key R&D Candidates
- The KOL View
- The mediKOL view
- Conclusions
- List of Tables & Charts included in this report:
- Global Multiple Sclerosis Market ($m) 2004-2007; Split by Leading Products
- Leading Products & New Therapies - Perceived Efficacy vs Safety/Side-Effect Issues
- Key Events by Product Timeline: 2008-2013
- Scenario 1: “Safer Brands Take Over”
- Scenario 2: “Tysabri and Fingolimod First Line”
- Scenario 3: “Status Quo Continues”
- Key Products incl. R&D Compounds: Perceived Efficacy vs Year of Launch (by Route of Administration)
- New Therapies (by Route of Administration): Perceived Efficacy vs Safety/Side-Effect Issues - I
- New Therapies (by Route of Administration): Perceived Efficacy vs Safety/Side-Effect Issues - II, Tysabri and fingolimid demonstrate low risk of PML
- Scenario 1: “Safer Brands Take Over”, Scenario 2: “Tysabri and Fingolimod First Line” & Scenario 3: “Status Quo Continues”
- Global Multiple Sclerosis Market ($m) 2004-2014; Scenarios 1-3
- Global Multiple Sclerosis Market ($m) 2004-2014; Scenario 1 (sales split by Product / Product Group
- Global Multiple Sclerosis Market ($m) 2004-2014; Scenario 2 (sales split by Product / Product Group
- Global Multiple Sclerosis Market ($m) 2004-2014; Scenario 3 (sales split by Product / Product Group
- Global Immunomodulator Market ($m) 2004-2014
- Global Oral Immunomodulator Market ($m) 2004-2014
Share this report
Other tasks Related Markets CNS/Neurology Reports- Traumatic Brain Injury Global Clinical Trials Review, H1, 2012
- Tension -Type Headache Global Clinical Trials Review, H1, 2012
- Cluster Headache Syndrome Global Clinical Trials Review, H1, 2012
- Cerebral Infarction (Brain Infarction) Global Clinical Trials Review, H1, 2012
- Brain Ischemia Global Clinical Trials Review, H1, 2012
Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
